Released Apr 13, 2018, after the close
10-Q filed May 15, 2018, 45 days after period end · 0001390478-18-000010
Q1 2018 · 10-Q
Revenue—
Net Income-$8.00M-$8.00M N/M vs Q1 2017N/M vs Q4 2017
EPS Diluted-$1.67-$1.67 N/M vs Q1 2017no prior Q4 2017 on file
Operating Cash Flow-$5,403,000N/M
What the release said
The release
Same quarter
| Metric | Q1 2018 | Q1 2017 | Q1 2016 | Q1 2015 |
|---|---|---|---|---|
| Revenue | — | — | — | $2.75M |
| Net Income | -$8.00M | -$4.60M | -$16.49M | -$10.54M |
| EPS Diluted | -$1.67 | -$3.63 | — | -$0.08 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR